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Cancer patientsAbstract Background and aim: In recent years, a few of the antibiotic-resistant bacteria, known as
ESKAPE pathogens, have been found responsible for serious infections. We investigated the risk
factors, and impact of ESKAPE pathogens on course of blood stream infections (BSIs) in cancer
patients in comparison to coagulase negative Staphylococci (CoNS).
Patients and methods: The data of patients with ESKAPE positive blood cultures at National
Cancer Institute, Cairo University were analyzed. Identification and antimicrobial susceptibility
of isolates were done using Microscan Walk Away 96.
Results: In a 6 month period, ESKAPE pathogens were isolated from non-duplicate blood cultures
in 81 episodes of 72 cases of pediatric cancer patients, while CoNS were isolated from 135 blood
cultures of 116 patients. The ESKAPE pathogens isolated were Enterobacter spp., methicillin-
resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Enterococci in 12%, 23%, 37%, 10%, 9%, and 9% of episodes,
respectively. Health-care acquired infections constituted 75% of ESKAPE infections. Duration
of episodes and overall mortality were significantly higher in ESKAPE BSIs when compared to
CoNS (14.5 ± 7.6 versus 09.9 ± 6.9), and (26% versus 4%); respectively, p value <0.001.
Conclusions: ESKAPE pathogens were significantly associated with higher rates of morbidity and
mortality indicating the need for improving the means of prevention of these types of infections
within health care premises. Microbiology laboratories have a role in defining more dangerous
infections and rapid diagnostics are required in the era of resistance.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Infections are still considered major causes of morbidity and
mortality in cancer patients [1]. Pediatric oncology patients
158 H.A. El-Mahallawy et al.with fever, even when not neutropenic, are known to be at an
increased risk of bloodstream infections (BSI) [2]. In the era of
increased resistance, better understanding of infectious agents
threatening patients with hematological malignancies and opti-
mizing supportive care against these agents with efforts to pre-
vent infections constitute life saving strategies. Gram positive
organisms, mainly Coagulase negative Staphylococci (CoNS)
constitute common causes of BSI in pediatric cancer patients
[3], especially with the increased use of central lines in this pop-
ulation of patients.
In recent years, the Infectious Diseases Society of America
has highlighted a fraction of antibiotic-resistant bacteria (Ente-
rococcus faecium, Staphylococcus aureus, Klebsiella pneumo-
niae, Acinetobacter baumannii, Pseudomonas aeruginosa and
Enterobacter spp.) – acronymically dubbed ’the ESKAPE
pathogens’ – capable of ‘escaping’ the biocidal action of antibi-
otics and mutually representing new paradigms in pathogene-
sis, transmission and resistance [4]. The ESKAPE pathogens
are responsible for a substantial percentage of nosocomial
infections in the modern hospital and represent the vast major-
ity of isolates whose resistance to antimicrobial agents presents
serious therapeutic dilemmas for physicians [5]. Therefore, we
attempted in this study to investigate the risk factors associ-
ated with blood stream infections caused by ESKAPE patho-
gens and their impact on the course of infectious episode, as
regards duration of episode, and outcome in comparison to
the more commonly isolated CoNS.Patients and methods
This is a Microbiology laboratory based retrospective study,
analysing the surveillance results of blood stream infections
in collaboration with the Pediatric Oncology department at
National Cancer Institute, Cairo University. National Cancer
Institute is a tertiary care cancer center. Health care associated
infection is an infection acquired within 72 h of patient hospi-
talization and patient was not in incubation period of infec-
tion. Feverish patients are investigated by blood culture
testing prior to receiving empirical antibiotic therapy. Fever
and neutropenia are defined according to the IDSA guidelines
[6]. The data of patients with non-duplicate ESKAPE and
CoNS positive blood cultures were collected from June to
December 2012 including their age, diagnosis, disease status,
hospitalization at day 1 of fever, co-morbidities, prior antibi-
otic intake in the previous month, last course of chemotherapy
received and concomitant clinical documented infections. This
study was approved by NCI Ethics Committee and an
informed consent was obtained from parents of participants.
Microbiology
Two blood culture sets were drawn from each patient within
the first day of fever from two separate veins. Bactec 9120
incubator was used. Identification of isolates was done using
microscan dried gram negative MIC/Combo and dried gram
positive MIC/Combo panels Seimens Healthcare Diagnostics
Ltd (Sir William Siemens Sq. Frimley, Cambeley, UK GU16
8QD). The panel of antibiotics used for Gram negative
included amikacin, amoxicillin–clavulanate, ampicillin-
sulbactam, aztreonam, cefepime, cefoperazone, ceftazidime,cefuroxime, ciprofloxacin, gentamycin, imipenem, meropenem,
norfloxacin, piperacillin, piperacillin–tazobactam, ticarcillin-
clavulanate. Antibiotics for Gram positive panels were trime
thoprim–sulfamethoxazole, clindamycin, erythromycin, gen-
tamycin, levofloxacin, linezolid, moxifloxacin, oxacillin, cefox-
itin, synercid, tetracycline, and vancomycin. The susceptibility
test results were interpreted according to the CLSI guidelines
[7]. The MDR phenotype referred to non-susceptibility to at
least one agent in three or more antimicrobial classes [8].
Management and course of the episode
Local hospital guidelines necessitate hospitalization of febrile
neutropenic patients to receive empirical therapy after risk
assessment. The primary lines of empirical regimen during this
period were either rocephin/amikacin (CRO/AK), or tazobac-
tam/amikacin (TZP/AK); with meropenem/amikacin (MEM/
AK) as the secondary line. Patients received an empirical anti-
fungal and an antiviral (zovirax) if fever persisted; and antibi-
otics continued until patients became afebrile and ANC
exceeded 0.5  109 L. Episodes were considered controlled
when fever resolved within 5–7 days. Persistent fever for more
than 7 days marked a prolonged episode. Mortality was
recorded within one month of the beginning of an episode.
Statistical methods
Data were analyzed using IBM SPSS advanced statistics ver-
sion 22 (SPSS Inc., Chicago, IL). Numerical data were
expressed as mean and standard deviation. Qualitative data
were expressed as frequency and percentage. Chi-square test
was used to examine the relation between qualitative vari-
ables. For not normally distributed quantitative data, com-
parison between two groups was done using Mann–
Whitney test (non-parametric t-test). The end points of the
study were the duration of the episode and outcome of infec-
tion. All tests were two-tailed. A p-value <0.05 was consid-
ered significant.
Results
In a period of 6 months, ESKAPE pathogens were isolated
from non-duplicate blood cultures n 81 episodes of 72 cases
of pediatric cancer patients receiving their chemotherapy in
the in-patient sector of Pediatric Oncology department of
NCI, Cairo University. In the same period, CoNS were iso-
lated from 135 blood cultures in 116 patients. The frequency
of ESKAPE pathogens in relation to the total episodes of
blood stream infections in febrile neutropenic pediatric cases
in a period of 6 months were 81/336 (24%), while the relative
frequency of CoNS were 135/336 (40%). The epidemiological
features of the cases included in the study and different risk
factors (health care associated infections, co-morbidities, prior
febrile episode, chemotherapy either standard or intensified,
clinically documented infections as mucositis, diarrhea, central
venous line infection and respiratory tract infection, are illus-
trated in Table 1. The difference in peripheral blood counts,
absolute neutrophilic count, monocyte and platelet counts,
together with duration of neutropenia are illustrated in
Table 2.
Table 1 Comparison of epidemiological data of two groups of blood stream infections in febrile neutropenic pediatric cases with










Age, years 6.550 ± 4.560 6.930 ± 4.620 0.478
Sex
 Male 45 (63) 74 (64) 0.858
 Female 27 (37) 42 (36)
Diagnosis
 ALL 29 (40) 38 (33) 0.317
 AML 16 (22) 20 (17)
 Lymphoma 10 (14) 16 (14)
 Solid tumors 17 (24) 42 (36)
Health-care associated infections
 No 21 (26) 54 (40) 0.041*
 Yes 60 (74) 81 (60)
Co-morbidities
 No 25 (31) 31 (23) 0.200
 Yes 56 (69) 104 (77)
Prior febrile episode
 No 32 (40) 54 (40) 0.943
 Yes 49 (60) 81 (60)
Last chemotherapy
 Standard 25 (31) 45 (33) 0.707
 Intensified 56 (69) 90 (67)
Clinical documented infections
 No 25 (31) 79 (59) <0.001*
 Yes 56 (69) 56 (41)
1. Mucositis 16 (20) 5 (4) <0.001*
2. CVL infection 10 (12) 6 (4) 0.032*
3. Diarrhea 11 (14) 14 (10) 0.475
4. Respiratory tract infection 31 (38) 27 (20) 0.003*
Values for age, sex and diagnosis were stated per patient, while the values for other parameters were for episodes.
ALL (Acute lymphoblastic leukemia), AML (Acute myeloid leukemia), CVL (central venous line).
* p Value 60.05 denoting significant.
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The ESKAPE pathogens isolated were Enterobacter spp.,
methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aerugi-
nosa, and Enterococci in 10 (12%), 19 (23%), 30 (37%), 8
(10%), 7 (9%), and 7 (9%) episodes, respectively. The results
of antibiotic susceptibility testing of ESKAPE pathogens
revealed that 60/81 (74%) were MDR and 21/81 (26%) were
antibiotic sensitive, while CoNS revealed that 56/135 (41.5%)
were MDR and 79/135 (58.5%) were sensitive, p value <0.001.
Management and course of BSI
Comparison between management as regards primary line of
therapy, shift of primary line to the secondary one, addition
of vancomycin, and an antifungal given is provided in Table 3.
The course of the episodes, mainly duration and outcome
within 2 weeks of first day of fever was recorded and thedifference between ESKAPE and CoNS infections is listed in
Table 3. Duration of episodes was significantly longer and
mortality rates were markedly higher among the cases infected
with ESKAPE pathogens. The relation of mortality with dif-
ferent types of pathogens within the ESKAPE blood stream
infections is illustrated in Fig. 1.Discussion
In recent medical practice, progress in supportive care following
cancer chemotherapy has been successful in improving the out-
come of patients with hematological malignancies. Yet, despite
these advances, infections remain a major cause of morbidity,
increase in healthcare costs and higher probability of disease
relapse as a result of delay in chemotherapy [9]. Therefore, clo-
ser understanding of infections occurring in this population of
patients may lead to better supportive care and subsequently
attain higher outcome rates. It is essential to focus on patients
with more risky infections, especially in the era of increasing
Table 2 Comparison between peripheral blood counts of episodes of ESKAPE and coagulase negative Staphylococci blood stream











 Day 1 1.300 ± 3.600 0.960 ± 2.090 0.290
 Day 4 0.700 ± 1.600 0.870 ± 1.790 0.357
 Day 7 0.600 ± 0.950 1.380 ± 3.260 0.050*
AMC
 Day 1 0.250 ± 0.760 0.320 ± 0.670 0.061
 Day 4 0.230 ± 0.360 0.390 ± 0.770 0.078
 Day 7 0.240 ± 0.320 0.460 ± 0.710 0.052
Platelets
 Day 1 111.800 ± 118.300 118.800 ± 128.500 0.641
 Day 4 91.800 ± 122.800 136.900 ± 151.500 0.006*
 Day 7 90.800 ± 114.300 161.600 ± 167.800 0.000*
Duration of neutropenia, days 10.200 ± 7.600 8.300 ± 7.900 0.032*
ANC (Absolute neutrophil count), AMC (Absolute monocytic count).
* p value 60.05 denoting significant.
Table 3 Comparison between clinical course and outcome of blood stream infectious episodes in febrile neutropenic pediatric cases











 Continued 50 (62) 119 (88) <0.001*
 Shift 31 (38) 16 (12)
Antibiotic added
 No 42 (52) 63 (47) 0.460
 Yes 39 (48) 72 (53)
Antifungal added
 No 30 (38) 76 (56) 0.010*
 Yes 49 (62) 59 (44)
Antibiotic at day7
 No 19 (25) 71 (53) <0.001*
 Yes 58 (75) 64 (47)
Day 4 evaluation
 No fever 18 (22) 60 (44) 0.001*
 Fever 63 (78) 75 (56)
Day7 evaluation
 No fever 13 (17) 71 (53) <0.001*
 Fever 63 (83) 64 (47)
Duration of episode days 14.500 ± 7.600 09.900 ± 6.900 <0.001*
Outcome
 Alive 53 (74) 111 (96) <0.001*
 Dead 19 (26) 5 (4)
* p value 6 0.05 denoting significant.
160 H.A. El-Mahallawy et al.antimicrobial resistance in a trial to modify local guidelines
accordingly and set protocols for prevention [10,11]. Thus, we
attempted to investigate the impact of ESKAPE pathogens on
the course of infectious episodes in comparison to CoNS thatare more commonly isolated from blood cultures of pediatric
patients with cancer at our institution [3].
In the present study, the ESKAPE pathogens were signifi-




















Figure 1 Mortality among different ESKAPE pathogens.
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BSIs, with a p-value of <0.001. Within the ESKAPE patho-
gens, Pseudomonas aeruginosa and Klebsiella pneumoniae
(Kp) were the most risky, with a mortality rate of 43% (3/7)
and 30% (9/30), respectively. In a multicenter retrospective
cohort study conducted in 3 large Italian teaching hospitals,
the overall-30-day mortality rate for BSIs caused by car-
bapenem resistant Kp was 42% [12]. A similar study reported
that persistence of bacteremia (25% vs. 9.7%), septic metasta-
sis (8% vs. 4%) and early case-fatality rate (23% vs. 11%)
were more frequent in patients with ESKAPE bacteremia than
in patients with other etiologies (p< 0.05) [13]. In a recent
study, comorbidities were independently associated with
ESKAPE pathogens, with an overall fatality rate of 34% in
the resistant ESKAPE bacteremic episodes and 22% in other
bacterial causes; with a p-value of 0.06 [14]. In the latter study,
sepsis persistence was more frequent in ESKAPE bacteremic
episodes than in bacteremia due to other etiologies (25% ver-
sus 9.7%, p-value 0.001) [14]. Thus, it was concluded that bac-
teremia due to ESKAPE pathogens is an emerging problem in
cancer patients especially among those with comorbidities
receiving prior antibiotic treatment.
In the current study, ESKAPE pathogens were significantly
associated with health care acquisition, p= 0.041. They were
also, significantly more encountered in cases with clinically
documented infections, p=<0.001, especially mucositis, cen-
tral line, and respiratory tract infections, p=<0.001, 0.032,
and 0.003; respectively. Similarly, prior hospitalization was
significantly associated with ESKAPE infections [15]. Other
risk factors that could predict ESKAPE pathogens, as prior
febrile episodes, type of leukemia, intensified chemotherapy,
and co-morbidities, did not differ in ESKAPE pathogens com-
pared to CoNS. In another study, factors independently asso-
ciated with ESKAPE bacteremia were prior transplantation,
septic shock, and prior antibiotic therapy. Patients with
ESKAPE BSIs received inappropriate empirical antibiotictherapy more often than the others (41% vs. 21.6%;
p= 0.01), and showed a higher overall case-fatality rate
(30 days) (35.2% vs. 14.4%; p= 0.001) [14].
Although reduced neutrophil, monocyte, and platelet
counts on day 1 in the present study did not show any differ-
ence between different causes of BSI, yet, peripheral blood
counts on day 7 and duration of neutropenia were signifi-
cantly less with longer duration of neutropenia in the infec-
tions caused by the ESKAPE pathogens. In a previous
study conducted in the same institution, reduced ANC on
day 1 was not associated with resistant bacterial infections,
whereas, monocytic and platelet counts and prolonged dura-
tion of neutropenia were significantly associated with
MDROs [16].
Febrile neutropenic patients with cancer are a heteroge-
neous population of patients with high risk to develop infec-
tions caused by a wide array of pathogens ranging from skin
flora up to highly virulent bacteria [17,18]. The findings of
the current study clarified the vast difference in the course of
blood stream infections resulting from the ESKAPE pathogens
when compared to the opportunistic CoNS. The antimicrobial
resistant ESKAPE pathogens were significantly associated
with higher rates of morbidity and mortality. Improving the
understanding of the virulence attributed to different patho-
gens implicated in infections in cancer patients must be accom-
panied by better control measures for a better supportive care
aiming at lower rates of infections caused by fatal pathogens in
order to reduce morbidity and mortality. A systematic
approach to surveillance, infection prevention, antimicrobial
stewardship and clinical guidelines ensure best practice for
infection control and management improving patient out-
comes and reduce the spread of antimicrobial resistance.
Microbiology laboratories in modern medicine have a role in
defining more dangerous infections & have to help in more
rapid diagnosis by introducing recent diagnostics that is
urgently required in the era of resistance to reduce the
162 H.A. El-Mahallawy et al.turn-around time; thus, avoiding the delay in diagnosis and
allowing patients to receive proper therapy in optimal time.
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